Kornimate/medical-research-clean huggingface dataset:
middle-aged and older adults with hypertension in rural communities

Conditions: Hypertension

Summary: does the m-health intervention have a positive effect on the health literacy and health promotion behaviors of the study participants?

this study adopted a mixed methods study, and the first stage was a qualitative research design. the second phase was a quantitative research design aims to evaluate the effectiveness of applying healthy lifestyle intervention on the health literacy and health promotion behaviors among middle-aged and older adults with hypertension in rural communities. recruitment is planned to be conducted in the cardiology outpatient clinic of a regional teaching hospital in the south. it will be a random assignment, single-blind, experimental research design, using simple random sampling to assign to the experimental group and the control group (experimental group: hypertension health education manual + m-health; control group: hypertension health education manual), a two- month intervention program was carried out, and the questionnaire survey was conducted three times: once as a pre-test and twice as post-tests (during the 4th week and the 8th week of the intervention). data analysis was conducted using statistical software (spss, version 22.0) for data management and statistical analysis, and analysis was conducted using descriptive statistics, independent sample t-test, chi-square test, and generalized estimating equations (gee).

Eligibility criteria:
inclusion criteria: 1. diagnosed with hypertension for one year or more (including) and controlled with medication (systolic blood pressure ≥ 130 mmhg and diastolic blood pressure ≥ 80 mmhg). 2. aware hypertensive patients aged ≥ 45 years with the ability to read and write. 3. able to take medication independently. 4. own a smartphone and are able to use it, and are willing to receive text messages (txtm) or mobile health interventions (m-health). 5. agree to participate in the study. exclusion criteria: 1. have cognitive impairments or mental disorders. 2. cci (charlson comorbidity index) score ≥ 3.

Keywords: hypertension rural health literacy health promotion middle-aged and older adults
effects of green coffee extract supplementation on adropin, irisin, vaspine,systemic inflammation and oxidative stress in breast cancer survivors

Conditions: Breast Cancer Survivors

Summary: to study the effects of green coffee supplement on adropin, irisin, vaspine, systemic inflammation and oxidative stress in breast cancer survivors.50 breast cancer survivors who their treatment is over and referred to follow breast cancer clinic with will be randomly allocated to receive placebos or 2 capsules green coffe for 12 weeks; both groups will be advised to adherence the investigators' diet and exercise program too. at the first and the end of the intervention, adropin, irisin, vaspine, systemic inflammation and oxidative stress will be assessed and compared between groups.


Eligibility criteria:
inclusion criteria: * age of 18 to 70 years * body mass index (bmi) between 25-40 treatment is over exclusion criteria: * taking any kind of supplement for weight reduction * pregnancy or lactation * professional athletes
periodontal changes following mid maxillary distraction

Conditions: Cleft Lip and Palate; Periodontal Pocket; Attachment Loss, Periodontal

Summary: to evaluate the health status of the periodontium and dentition at the distraction osteogenesis site in clp subjects using mid maxillary distraction (mmd).

segmental forward maxillary distraction osteogenesis(do)was performed. distractor connecting buccal molar segments to the anterior maxilla was kept for 7 days. then distraction was performed till overcorrection and consolidated for 3-months. periodontal clinical parameters were recorded at baseline, 3 and 6-months postoperatively. gingival crevicular fluid was collected . soft tissue healing was evaluated clinically and histologically after distraction.

Eligibility criteria:
inclusion criteria: * severe maxillary hypoplasia and negative anterior overjet exclusion criteria: * systemic disease

Keywords: inflammation healing distraction periodontium
effect of ril-21 on metastases in lymph nodes in melanoma skin cancer

Conditions: Cancer; Malignant Melanoma

Summary: the trial is conducted in europe. this trial aims for a comparison of the pathology in lymph nodes before and after the effect of recombinant interleukin-21 in patients with stage iii melanoma

the decision to discontinue the nn028-1801 trial is not due to any safety concerns. the trial was terminated as a result of a strategic decision by the sponsoring company.

Eligibility criteria:
inclusion criteria: * stage iii melanoma * ecog performance status 0-1 exclusion criteria: * signs of stage iv melanoma * safety variables
a study to assess the efficacy and safety of ro7790121 in participants with moderate to severe atopic dermatitis

Conditions: Atopic Dermatitis

Summary: the purpose of this study is to assess the efficacy and safety of ro7790121 in participants with moderate to severe atopic dermatitis (ad).


Eligibility criteria:
inclusion criteria: * ad diagnosis confirmed by a dermatologist according to the hanifin/rajka criteria at least 1 year prior to screening * moderate to severe ad * at least once daily use of an additive-free, bland emollient for at least 7 days prior to the baseline visit and during the study exclusion criteria: * evidence of other skin conditions that would interfere with the assessment of ad, including, but not limited to, for example cutaneous t-cell lymphoma, allergic contact dermatitis * iv, im, il, and oral corticosteroids (inhaled, ophthalmic drops, and nasal corticosteroids are allowed) within 4 weeks of the baseline visit and during the study * topical treatment for ad including, but not limited to topical corticosteroids, topical calcineurin inhibitors, topical pde-4 inhibitors, , prescription moisturizers or moisturizers containing additives such as ceramide, hyaluronic acid, urea or filaggrin within 7 days prior to the baseline visit and during the study * any active infection or other active skin diseases that required treatment with parenteral anti-infectives within 4 weeks or oral anti-infective treatment within 2 weeks prior to baseline * acquired or congenital immunodeficiency * systemic therapies that are also used in the treatment of ad, including, but not limited to methotrexate, cyclosporine, azathioprine, mycophenolate mofetil within 4 weeks of the baseline visit and during the study
a phase 2 trial of alimta (pemetrexed) in locally advanced or metastatic recurrent transitional cell carcinoma of the urothelium

Conditions: Urologic Neoplasms; Metastases, Neoplasm

Summary: patients with bladder cancer will be participating in this study for the treatment of abnormal cells in the bladder that have returned after initial treatment or have moved to a new site in the body.


Eligibility criteria:
inclusion criteria: * you must have been diagnosed with bladder cancer that has recurred or moved to a new part of the body. * you must have at least one tumor that can be physically measured or scanned by x-ray. * you may not have had previous chemotherapy (drug) treatment or you have had surgery followed by one chemotherapy treatment at least 4 months ago. exclusion criteria: * you may not have used an experimental medicine or device within the past month. * cancer that has spread to your brain. * if you are unwilling or unable to take folic acid or vitamin b12 supplements.

Keywords: bladder cancer metastatic recurrent transitional cell carcinoma of the urothelium
comparison of usual care and distraction (tablet) in children 3-5 years old

Conditions: Anxiety

Summary: randomized control trial comparing usual care and distraction (tablet) on anxiety, emergence delirium, sedation/agitation, and vomiting in children 3-5 years old

two group rct comparing usual care (midazolam) and distraction (tablet) on preoperative anxiety, emergence delirium, sedation/agitation, and vomiting in preschool children 3-5 years old.

Eligibility criteria:
inclusion criteria: * 3-5 year old children * scheduled for elective surgery * american society of anesthesiologists physical status classification system: i - ii exclusion criteria: * children younger than 3 or older than 6 * allergy to midazolam * cognitive or developmental delays * american society of anesthesiologists physical status classification system: iii - vi * anesthesia provider determines child is not eligible * children that are transferred to icu after surgery
evaluation of patient performance using the metoject device for subcutaneous injection in rheumatoid arthritis (ra)patient

Conditions: Rheumatoid Arthritis (RA)

Summary: to evaluate the human factors/usability of rheumatoid arthritis (ra) patients with the metoject® prefilled pen (including a label comprehension assessment and a device robustness evaluation).


Eligibility criteria:
inclusion criteria: * is a suitable candidate for treatment with methotrexate for rheumatoid arthritis * male or female patient who is 16 years of age or older exclusion criteria: * is a female patient who is pregnant, trying to become pregnant, or breast feeding, or of childbearing potential, sexually active and not practicing a highly reliable method of birth control during the study and at least 6 months thereafter * has any history of hypersensitivity to the investigational medicinal product * has a history of or current inflammatory arthritis or rheumatic autoimmune disease other than rheumatoid arthritis (ra) * is unable to comprehend written labeling and training materials
ranibizumab for diabetic traction retinal detachment

Conditions: Diabetic Retinopathy; Retinal Detachment

Summary: the purpose of this study was to assess the effect of ranibizumab in reducing intraoperative vitreous haemorrhage during pars plana vitrectomy, thus facilitating surgery and improving its anatomical and functional results in patients with advanced proliferative diabetic retinopathy and traction retinal detachment.


Eligibility criteria:
inclusion criteria: * macular traction retinal detachment lasting three months or less secondary to diabetic retinopathy. exclusion criteria: * massive vitreous hemorrhage preventing from detailed posterior pole examination; * previous intra-ocular surgery other than cataract surgery * hemodialysis, known bleeding disorders or use of anticoagulants drugs other than aspirin * prothrombin time, partial thromboplastin time or platelet count without normal limits * history of previous thromboembolic events

Keywords: diabetic retinopathy retinal detachment vitreous hemorrhage preoperative ranibizumab pars plana vitrectomy
effectiveness of a cancer center based physical activity intervention

Conditions: Breast Cancer; Quality of Life; Physical Activity

Summary: purpose: examine the effectiveness of cancer center-based physical activity counseling on physical activity rates and quality of life in breast cancer survivors. hypothesis: participants in the intervention group will indicate greater step counts and quality of life at the end of the intervention compared to the control group


Eligibility criteria:
inclusion criteria: * diagnosis of breast cancer within the last 5 years * over the age of 18 years * female exclusion criteria: * non-ambulatory * poor cognitive function * contraindications for exercise as determined by the par-q
a prospective, multicenter, observational cohort study assessing the efficacy and safety of radiotherapy-sensitized immunotherapy in advanced breast cancer

Conditions: Advanced Breast Cancer

Summary: a prospective, multicenter, observational cohort study assessing the efficacy and safety of radiotherapy-sensitized immunotherapy in advanced breast cancer.


Eligibility criteria:
inclusion criteria: subjects are eligible for inclusion in the study only if all the following criteria apply: 1. men or women who are 18 years of age or older on the day of signing the informed consent; 2. patients with advanced breast cancer that is inoperable or has metastasized, confirmed by histology or cytology; 3. patients who, after mdt discussion at the metastatic breast cancer stage, are considered suitable for radiotherapy and have completed radiotherapy; 4. patients who have previously received and continue to use immunotherapy, or are planned to receive immunotherapy, and are scheduled to receive a systemic treatment regimen including immunotherapy as chosen by the physician within 3 weeks after completing radiotherapy; 5. patients with a traceable medical history during treatment; 6. subjects who are able to sign an informed consent to participate in the study. exclusion criteria: 1. subjects with brain metastases or leptomeningeal metastases; if there are any suspected symptoms or signs of cns involvement, they should be excluded by a cranial mri scan; 2. have not signed the informed consent form; 3. pregnant or lactating women; 4. other conditions deemed unsuitable for inclusion in the study by the investigator.
a bioavailability study of gsk1363089 in subjects with solid tumors

Conditions: Solid Tumours

Summary: study to compare 2 different chemical forms of gsk1363089.


Eligibility criteria:
inclusion criteria: * histologically or cytologically confirmed diagnosis of solid tumor malignancy. * 18 years old with ecog of 0-1. * female subject who is not pregnant * male subjects must agree to use contraception methods * able to swallow and retain oral medication. * the subject will refrain from the use of illicit drugs and adhere to other protocol-stated restrictions while participating in the study. * qtcb or qtcf \< 470 msec. * bilirubin = 1.5mg/dl, ast, alt, alp \<2x uln in absence of malignant disease in the liver or \<5x uln in case of liver involvement by the tumor. * serum creatinine \<1.5mg/dl exclusion inclusion: * the subject has received anticancer treatment. * the subject has participated in a clinical trial and has received an investigational product within 21 days. * the subject has known brain metastases. * the subject has uncontrolled intercurrent illness. * history of sensitivity to any of the study medications, or components. * the subject is known to be positive for the human immunodeficiency virus (hiv). * subjects who have had partial or complete gastrectomy. * pregnant females as determined by positive ß-hcg test at screening or prior to dosing. * lactating females. * unwillingness or inability to follow the procedures outlined in the protocol.

Keywords: pharmacokinetics safety met bioavailability patients gsk1363089a gsk1363089g gsk1363089 relative
effect of hilt vs lllt in treatment of patients with achilles tendinitis or plantar fasciitis

Conditions: Plantar Fascitis; Achilles Tendon Pain

Summary: the aim of this study is to evaluate and compare the changes of heel pain, functional health and well-being after high-intensity and low-level laser therapy for plantar fasciitis or achilles tendinopathy

plantar heel pain, also known as plantar fasciitis, causes soreness or tenderness of the sole of the foot under the heel, which sometimes extends into the medial arch. pain associated with the condition may cause substantial disability and poor health-related quality of life. achilles tendinitis is a common etiology of posterior heel pain that results in significant pain and loss of function. calf exercise is initial management that may be supported by laser therapy. a treatment possibility high-intensity laser therapy is little explored. high-intensity lasers can deliver more energy deeper into tissue. the hypothesis is that both lasers are effective in treatment of plantar fasciitis or achilles tendinopathy, but high-intensity laser therapy is more effective. the aim of this study is to evaluate and compare the changes of heel pain, functional health and well-being after high-intensity and low-level laser therapy for plantar fasciitis or achilles tendinopathy. the study was approved by committee on biomedical research ethics of kaunas region (2016-07-14 no. be-2-32). patients are recruited in out patient clinic of physical medicine and rehabilitation department in the hospital of lithuanian university of health sciences (lsmu) kauno klinikos.

Eligibility criteria:
inclusion criteria: * unilateral painful activity related symptoms from the achilles region * tenderness during palpation of achilles insertion on calcaneus or couple centimeters above * unilateral plantar heel pain, mainly during the first few steps upon rising in the morning * tenderness at the insertion site of the plantar fascia o the calcaneus exclusion criteria: * bilateral heel pain * other acute pathology (febrile fever, cold. etc.) that require treatment * other painful conditions that require painkillers (tooth pain, back pain, etc) * pregnancy * history of recent trauma or foot surgery * wounds, infections in treatment area * impaired sensation in treatment area * pigmentation changes on the skin in treatment area (tattoo, birthmarks) * received oral or injected corticosteroids within the last 26 weeks * diagnosis of systemic inflammatory arthritis (goat, rheumatoid arthritis, etc) * diagnosis of neurological heel pain (radiculopathy) * diagnosis of other heel pathology (calcaneal stress fracture, osteomyelitis, plantar fascia neoplasm, plantar fascia rupture, etc)

Keywords: high-intensity laser therapy low-level laser therapy
the effect of pioglitazone and rosiglitazone on atherosclerotic and inflammatory markers in patients with metabolic syndrome

Conditions: Metabolic Syndrome

Summary: pioglitazone and rosiglitazone are used in the treatment of diabetic patients. thiazolidinediones increase insulin sensitivity and show favorable effect blood glucose levels and lipid profiles. the effect of these two different thiazolidinediones on atherosclerotic and inflammatory markers has not been compared in prospective manner. the purpose of this prospective, randomized, open-label, crossover trial is to compare the effect of pioglitazone and rosiglitazone on atherosclerotic and inflammatory markers in patients with metabolic syndrome.


Eligibility criteria:
inclusion criteria: * patients with at least 3 metabolic syndrome criteria of asian-pacific atp iii guideline: fasting blood glucose ≥ 110 mg/dl, systolic blood pressure ≥ 130 mmhg or diastolic blood pressure ≥ 85 mmhg, triglyceride ≥ 150 mg/dl, hdl-cholesterol \< 40 mg/dl for men and \< 50 mg/dl for women. * age: 18 years and above exclusion criteria: * hypertensive patients with the use of ace inhibitor or arb * hyperlipidemic patients with the use of statin or fenofibrate * patients with any contraindications to the treatment of thiazolidinediones * pregnant or lactating patients * chronic alcohol or drug abuse * hepatic dysfunction * renal dysfunction * heart failure (ef \< 50%) * expected life expectancy of \< 1 year

Keywords: rosiglitazone pioglitazone fmd pwv atherosclerosis
a mobile application, oncpatient, to assist patients undergoing radiation therapy

Conditions: Hematopoietic and Lymphoid Cell Neoplasm; Malignant Solid Neoplasm

Summary: this clinical trial determines how well the oncpatient mobile application work in assisting patients undergoing radiation treatment. radiation therapy can be complex. the technology, daily treatments, and possible side effects can be confusing to prevent and manage. traditional radiation patient education includes a large amount of information, including details of treatment logistics, side effect prevention, and management. however, this information is not always readily accessible or memorable through the long course of therapy, and critical details can be missed. oncpatient is a mobile application intended to be a more convenient and accessible form of patient education and guidance that is readily available to help patients and their caretakers navigate through radiation treatment.

primary objective: i. to determine the feasibility of implementing a mobile application designed to be an educational resource designed for patients undergoing radiation treatment. secondary objectives: i. to assess patient opinions on the usability and helpfulness of the mobile application in helping them through radiation treatments. ii. to assess satisfaction with the mobile application and radiation treatment. iii. to assess opinions on existing or new features for the mobile application to be given to future patients. outline: patients use the oncpatient mobile application over the course of radiation therapy. patients also complete a survey on the final day of radiation treatment.

Eligibility criteria:
inclusion criteria: * age 18 and older. * can read and speak english and provide informed consent. * diagnosed with cancer, any stage, any disease site. * must be consented to undergo a course of radiotherapy, starting within one month. no limits on duration of radiation apply. patients must be consented prior to initiating radiotherapy, however. * has regular access to a mobile device. * note: this requirement unfortunately leads to the exclusion of underserved patients who cannot afford to have a mobile device. given that the goal of this study is to establish feasibility of a mobile application, there are no true alternatives, given that these patients would require access to a mobile device if this app were commercially available. however, for impacted patients, the relevant application and resources will be made available on ipads they can access during treatment and a website they can access on any web-enabled device, to ensure they have access as much as reasonably possible. future iterations of the application will aim to increase access to the resource however possible, but limitations will always apply due to how the core functionality of the app requires a mobile device. exclusion criteria: * less than 18 years old. * non-english speaking. * inability to operate a mobile device.
phase iii randomized trial of adjuvant chemotherapy with s-1 vs s-1/oxaliplatin ± radiotherapy for completely resected gastric adenocarcinoma : the artist ii trial

Conditions: Gastric Cancer

Summary: the optimal regimen for adjuvant treatment has not been established in gc yet. we plan to compare ts-1, ts-1/oxaliplatin with or without rt in d2 resected gastric cancer.


Eligibility criteria:
inclusion criteria: 1. histologically proven gastric or gastroesophageal adenocarcinoma 2. ≥ d2 lymph node dissection, curative gastrectomy 3. stage ii, iii (ajcc 2010) with any n (any stage with n0 will be excluded) 4. age \> 19 5. ecog 0-2 6. no distant metastasis 7. adequate bone marrow functions (anc ≥ 1,500/ul, blood platelet ≥ 100,000/ul, haemoglobin ≥ 10g/dl, transfusion allowed) 8. adequate renal functions(serum creatinine ≤ 1.5mg/dl) 9. liver functions (serum bilirubin ≤ 1.5mg/dl, ast/alt ≤ 3 times(normal value) 10. written informed consent 11. possible oral intake (food, drug) exclusion criteria: * subjects presenting with any of the following will not be included in the study 1. active infection requiring antibiotics 2. pregnant, lactating women 3. concurrent systemic illness not appropriate for chemotherapy 4. resection margin (+) at permanent pathology 5. pathologic stage i or iv (ia or ib according to ajcc 2010) 6. inadequate surgery including d0, d1 resection, dissected lns less than 12 7. paraaortic lymph node (+), pathologically proven 8. women of potential childbearing not employing adequate contraception